Overall Status

Completed (2)

Withdrawn (1)

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

Masonic Cancer Center, University of Minnesota (1)

Seagen Inc. (1)

Collaborator

Intervention

brentuximab vedotin (1)

cd3+ teff cells (1)

cyclophosphamide (1)

fludarabine (1)

hum-195/rgel (1)

total body irradiation (1)

treg cells (1)

umbilical cord blood transplantation (1)

Study Documents

Intervention Type

drug (3)

biological (1)

radiation (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

anemia, refractory, with excess of blasts

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Minneapolis (biological, drug, radiation)

Withdrawn

Hematologic Malignancy
+16 more

Treg cells
+5 more

Minneapolis, Minnesota

Masonic Cancer Center, University of Minnesota

Nov 29, 2017

Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts Trial in United States (brentuximab

Completed

Has Results

Acute Lymphoid Leukemia
+3 more

brentuximab vedotin

Birmingham, Alabama
+28 more

Feb 5, 2016

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Disorders Trial in Houston (Hum-195/rGel)

Completed

Acute Myeloid Leukemia
+3 more

Hum-195/rGel

Houston, Texas

UT MD Anderson Cancer Center

Apr 1, 2013